SCHEMBL5585631

SCHEMBL5585631

CN(C)CCOc1ccccc1O

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.64
LMNA P02545 1/20 0.64
GAA P10253 1/20 0.64
MAPT P10636 1/20 0.64
HTR7 P34969 3/20 0.62
HTR1B P28222 2/20 0.59
DRD2 P14416 2/20 0.56
DRD4 P21917 2/20 0.56
DRD1 P21728 1/20 0.56
DRD5 P21918 1/20 0.56
ALDH1A1 P00352 4/20 0.55
KDM4E B2RXH2 3/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
CHRNB2 P17787 1/20 0.50
CHRNA4 P43681 1/20 0.50
HRH1 P35367 1/20 0.49
ADRB2 P07550 1/20 0.49
ADRB1 P08588 1/20 0.49
LTA4H P09960 1/20 0.49
DRD3 P35462 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1477065 0.91 JAK2 (0.62) JAK2LMNAGAAMAPTHTR7
SCHEMBL11266289 0.83 DRD2 (0.59) HTR7HTR1BDRD2DRD4DRD1
SCHEMBL22138621 0.82 HTR1B (0.53) JAK2LMNAGAAMAPTHTR7
SCHEMBL2637278 0.81 GAA (0.95) JAK2LMNAGAAMAPTDRD2
SCHEMBL5585586 0.81 HTR7 (0.69) HTR7HTR1BDRD2DRD4DRD1
SCHEMBL9045649 0.79 GAA (0.82) JAK2LMNAGAAMAPTDRD2
SCHEMBL5621969 0.79 GAA (0.82) JAK2LMNAGAAMAPTDRD2
SCHEMBL8352887 0.78 HTR7 (0.65) HTR7HTR1BDRD2DRD4DRD1
SCHEMBL2459518 0.78 HTR7 (0.65) MAPTHTR7HTR1BDRD2DRD4
SCHEMBL30862623 0.78 HTR7 (0.77) LMNAHTR7HTR1BDRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114450284-B 6, 7-Dihydro-5H-pyrido [2,3-C ] pyridazine derivatives as BCL-XL protein inhibitors 法国施维雅药厂 2024-05-07 CN disclosed
CN-114450284-A 6, 7-dihydro-5H-pyrido [2,3-C ] pyridazine derivatives and related compounds as BCL-XL protein inhibitors and pro-apoptotic agents for the treatment of cancer 法国施维雅药厂 2022-05-06 CN disclosed
US-7226925-B2 Compounds, their use and preparation BIOVITRUM AB (SE) 2007-06-05 US disclosed
EP-1513831-A1 NOVEL COMPOUNDS, THEIR USE AND PREPARATION Biovitrum AB (SE) 2005-03-16 EP disclosed
EP-1092716-B1 Derivatives of benzothiophenes, benzofurans and indoles, method for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-02-16 EP disclosed
EP-1275641-B1 Benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-01-12 EP disclosed
US-20040029888-A1 Novel compounds, their use and preparation PROXIMAGEN NEUROSCIENCE PLC (GB) 2004-02-12 US disclosed
WO-2004000830-A1 NOVEL COMPOUNDS, THEIR USE AND PREPARATION BIOVITRUM AB (SE) 2003-12-31 WO disclosed
US-6541471-B1 Useful as a TXA2 receptor antagonist and a 5-HT2 receptor antagonist LES LABORATOIRES SERVIER (FR) 2003-04-01 US disclosed
EP-1275641-A2 Benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2003-01-15 EP disclosed
EP-0955299-B1 Benzothiophene, benzofurane and indole derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2002-03-13 EP disclosed
US-6302837-B1 ANTICOAGULANTS ADIR ET COMPAGNIE (FR) 2001-10-16 US disclosed
EP-1092716-A2 Derivatives of benzothiophenes, benzofurans and indoles, method for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 2001-04-18 EP disclosed
US-6048875-A CARDIOVASCULAR DISORDERS; REDUCING THROMBOSIS ADIR ET COMPAGNIE (FR) 2000-04-11 US disclosed
EP-0955299-A1 Benzothiophene, benzofurane and indole derivatives, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1999-11-10 EP disclosed
EP-0014745-B1 CURING AGENT FOR POLYEPOXIDES, CURABLE EPOXY RESIN COMPOSITIONS, HARDENED PRODUCTS THEREFROM AND PROCESS FOR CURING A POLYEPOXIDE DIAMOND SHAMROCK CORPORATION (US) 1983-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029888-A1 Novel compounds, their use and preparation TPH1, TPH2, HTR1A JAK2 4082/4885LMNA 2647/4885GAA 658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.